Hengyi Petrochemical (000703.SZ) plans to spend 500 million to 1 billion yuan to implement a buyback.

20:40 22/01/2026

PetroChina Yantai (000703.SZ) disclosed the sixth-phase share repurchase program through centralized competitive trading, with the intention of repurchasing shares for the implementation of employee shareholding plans or equity incentives. The total amount of funds for this share repurchase is not less than 500 million yuan and not more than 1 billion yuan. The price of this share repurchase shall not exceed 15.00 yuan per share. The repurchase period shall not exceed 12 months from the date of approval of this repurchase program by the board of directors.

Hengyi Petrochemical (000703.SZ) disclosed a plan to repurchase shares through centralized competitive trading (the sixth phase). The company intends to repurchase shares for the implementation of an employee shareholding plan or equity incentive. The total amount of funds for this repurchase of shares is not less than 500 million yuan and not more than 1 billion yuan. The price for this repurchase of shares shall not exceed 15.00 yuan per share. The repurchase period shall not exceed 12 months from the date of approval by the board of directors of this repurchase plan.

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.